Business Development Director

Alimentiv is a specialized contract research organization (CRO) that is deeply committed to advancing human health by transforming the landscape of gastrointestinal (GI) clinical trials. For pharmaceutical and biotechnology companies navigating the complexities of drug development, particularly for GI and liver diseases, Alimentiv serves as a dedicated partner. These clients often face significant challenges, including slow patient recruitment, variability in clinical trial data, and lengthy development timelines, which can hinder the progress of bringing new, life-changing therapies to patients who desperately need them. We understand these hurdles intimately, which is why we have built a comprehensive suite of services designed to accelerate and enhance every stage of the clinical trial process. Our customers benefit from our integrated approach, which combines deep scientific and medical expertise in gastroenterology with operational excellence and cutting-edge technologies.

Our approach is centered on providing tailored solutions that address the specific needs of our clients and their research goals. We offer a full spectrum of services, from early-phase clinical development to post-market studies. This includes expert clinical trial design, meticulous medical imaging analysis, and advanced precision medicine services through our specialized laboratories like AcelaBio. By leveraging our global network of over 5,000 clinical trial sites and a vast network of key opinion leaders, we help our customers expedite study start-up and maximize patient enrollment, ensuring their trials are both efficient and impactful. We are pioneers in utilizing innovative technologies, such as artificial intelligence for histological analysis and endoscopy video scoring, to provide more precise and objective data. This commitment to innovation not only improves the quality of clinical trial outcomes but also helps our clients de-risk their development programs and accelerate their journey to market. Ultimately, our goal is to ensure that patients with debilitating GI conditions have faster access to the effective treatments they deserve.